Trial Information
The Role of MRI Perfusion to Detect Locally Recurrent or Persistent Disease in Prostate Carcinoma Treated With Radiation Therapy - A Pilot Study
Inclusion Criteria:
- Previously have had radical radiotherapy for localised prostate cancer
- Due to undergo routine post-treatment prostatic biopsies
- Suitable for MRI scan
- Adequate renal function
- No previous reaction to gadolinium
- Able to give informed consent
- No recent prostate biopsy within 6 weeks of enrolment
- Performance status (Eastern Cooperative Oncology Group [ECOG]) 0 or 1
Exclusion Criteria:
- Not suitable for MRI scan
- Previous reaction to gadolinium
- Impaired renal function
- Inability to give informed consent
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To determine whether there may be a role for MRI perfusion in the detection of recurrent or persistent prostatic cancer after previous radiotherapy
Principal Investigator
Michael Milosevic, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Princess Margaret Hospital, Canada
Authority:
Canada: Ethics Review Committee
Study ID:
UHN REB 03-0272-CE
NCT ID:
NCT00230386
Start Date:
May 2003
Completion Date:
Related Keywords:
- Prostatic Neoplasms
- Neoplasms
- Carcinoma
- Prostatic Neoplasms